The Journal of Pediatrics
Volume 142, Issue 6 , Pages 601-603 , June 2003

Is there a role for corticosteroids in Kawasaki disease?

References 

  1. Garrison FH. History of medicine. 4th ed. Philadelphia (PA): WB Saunders; 1929;
  2. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Jap J Allergol. 1979;16:178–222
  3. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al.  The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341–347
  4. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al.  A single intravenous infusion in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633–1639
  5. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. 1997;131:888–893
  6. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease. Pediatr. 1995;96:1057–1061
  7. Rowley AH, Shulman ST, Mask CA, Baker SC. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol. 2001;166:1334–1343
  8. Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease. J Pediatr. 2003;142:611–616
  9. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics. 2000;105:e78
  10. Raman V, Kim J, Sharkey A, Chatila T. Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J. 2001;20:635–637
  11. Takagi N, Kihara M, Yamaguchi S, Tamura K, Yabana M, Tokita Y, et al.  Plasma exchange in Kawasaki disease. Lancet. 1995;346:1307
  12. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996;128:146–149
  13. Dahlem PG, von Rosenstiel IA, Lam J, Kuijpers TW. Pulse methylprednisolone therapy for impending cardiac tamponade in immunoglobulin-resistant Kawasaki disease. Int Care Med. 1999;25:1137–1139
  14. Dale RC, Saleem MA, Daw S, Dillon MJ. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr. 2000;137:723–726
  15. Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re-treatment for immune globulin-resistant Kawasaki disease. Pediatr Intern. 2001;43:211–217
  16. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary involvement. Pediatr. 1979;63:175–179
  17. Kijima Y, Kamiya T, Suzuki A, Hirose O, Manabe H. A trial procedure to prevent aneurysm formulation of the coronary arteries by steroid pulse therapy in Kawasaki disease. Jap Circ J. 1982;46:1239–1242
  18. Kusakawa S. Long-term administrative care of Kawasaki disease. Acta Paediatr Jap. 1983;25:205–209
  19. Nonaka Z, Maekawa K, Okabe T, Eto Y, Kubo M. Randomized controlled study of intravenous prednisolone and gamma globulin treatment in 100 cases with Kawasaki disease. In: Proceedings of 5th International Kawasaki Disease Symposium 328-31. Amsterdam: Elsevier Science BV; 1995;p. 328–331
  20. Shinohara M, Sone K, Tomomasa T, Morikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr. 1999;135:465–469
  21. Newburger JW. Treatment of Kawasaki disease: corticosteroids revisited. J Pediatr. 1999;135:411–413

☆ Reprint requests: Stanford T. Shulman, MD, Professor of Pediatrics, Northwestern University, The Feinberg School of Medicine, Head, Division of Infectious Diseases, The Children’s Memorial Hospital, 2300 Children’s Plaza, Box #20, Chicago, IL 60614.

☆☆ J Pediatr 2003;142:601-3.

PII: S0022-3476(03)00204-X

doi: 10.1067/mpd.2003.258

The Journal of Pediatrics
Volume 142, Issue 6 , Pages 601-603 , June 2003

Article Tools